Tag: GlobeNewswire

Debuts at Innovation Forum to Record Attendance 

CHICAGO and LONDON, Oct. 06, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, introduced the Descartes Agent Control Plane at its Innovation Forum in Chicago, which this year brings together a record number of customers, speakers and sponsors to explore innovation in supply chain and logistics technology. Built on the Descartes Global Logistics Network™ (Descartes GLN™), the Agent Control Plane is designed to build trust in AI agents by coordinating them across applications and trading partners to execute multi-step workflows within defined guardrails, policies and human oversight.

“Even with connected systems, supply chain teams devote significant time to interpreting updates from emails, messages and portals, rekeying information and coordinating next steps to move orders forward,” said Ken Wood, Executive Vice President, Product Management at Descartes. “The Agent Control Plane brings our logistics capabilities together so AI agents can take on more of that work across applications, conversations and company boundaries; keep it moving as replies and approvals arrive; and act on events as they occur within permissions and approval points defined by customers. It’s an important step in our AI strategy, helping customers build on the Descartes solutions and AI platforms they already use and apply AI to the operational outcomes that matter, from reducing manual follow-up to keeping customer commitments on track.”

The Agent Control Plane combines the operationally ready data and connectivity of the Descartes GLN with capabilities from Descartes solutions to help AI agents coordinate work across applications and trading partners, and to make Descartes agents available within the AI platforms customers already use. The GLN supplies the logistics context to connect changes in one part of a shipment’s journey with actions needed elsewhere, while the Agent Control Plane applies customer-defined permissions and approvals and maintains a traceable record of agent actions. Together, they help reduce manual handoffs, accelerate responses to changing conditions and give teams more time to focus on exceptions and customer relationships.

“We’re pleased to welcome such a strong community of customers, sponsors and speakers to this year’s Innovation Forum,” said Edward J. Ryan, CEO at Descartes. “Record participation reflects the value of bringing this community together to share experiences, learn from one another and explore new possibilities. The conversations we have here help us understand our customers’ priorities and shape how we continue to innovate in support of their success.”

Bringing together 1,000+ attendees and 200+ speakers this year, the three-day Innovation Forum features sessions across fleet performance management, transportation management, global trade intelligence, logistics service providers and ecommerce operations. Industry and customer presentations, discussions with Descartes product specialists and hands-on demonstrations at the Technology Fair give attendees opportunities to explore practical ways to improve operations and gain more value from their technology investments.

To learn more about event speakers, sessions and sponsors, visit www.descartes.com/innovation-forum.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack
Tel: 226-750-8050
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ logistics and supply chain solution offerings and potential benefits derived therefrom; the innovations Descartes intends to present at its Innovation Forum in Chicago; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, Descartes undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for small to mid-sized biotech and pharmaceutical companies.

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical evaluation. The planned Phase 1 program is designed to establish the initial safety, tolerability and pharmacokinetic profile of MB-204 in humans, while generating clinical data to inform subsequent development. This transition is supported by encouraging preclinical findings, with MB-204 demonstrating immediate, robust and durable effects, including measurable carry-over effects following cessation of treatment, across multiple mouse models relevant to neurodevelopmental disorders, including Oprm1, Rett and Fragile X models. Together, these findings provide a scientific rationale for advancing MB-204 into clinical development and establishing its initial human safety and pharmacokinetic profile.

“We are pleased to begin moving forward into a Phase I trial for MB-204 in partnership with Novatech following the recent closing of our private placement and signing of a letter-of-intent,” said Marvel’s CEO Rod Matheson. “Novatech provides end-to-end clinical trial management, site selection, regulatory and ethics submissions, biostatistics, data management, and medical writing. They have an early-phase clinical focus including First-in-Human and proof-of-concept studies. The trial will be conducted in Australia which offers a streamlined and favourable regulatory environment as well as a generous 43% tax credit. We look forward to updating the market on our single ascending dose and multiple ascending dose studies as we progress. This marks Marvel’s transition from a pre-clinical to clinical phase company.”

Corporate Update:

• The Phase I single ascending dose (SAD) study is expected to begin in Q4 of 2026. The SAD study is designed to test the safety, tolerability and pharmacokinetics (PK) of MB-204 as well as include a potential biomarker and several cognitive endpoints. The data from the SAD will inform the design of the subsequent multiple ascending dose (MAD) study.
• Marvel has previously developed a novel liquid-based formulation of MB-204 for its Phase 1 trial SAD study which improved the drug’s PK in pre-clinical studies and may facilitate administration in patient populations where swallowing solid dosage forms may present challenges. The work was conducted with a grant from the National Research Council of Canada.
• The Company is currently preparing manuscripts for scientific publication and will provide a future update on conference participation.
• In collaboration with the iBrain Inserm Lab, Marvel is planning an upcoming experiment to test the efficacy of MB-204 against Yamo Pharmaceuticals’ L1-79 (repurposed racemic N-methyl Tyrosine) in a mouse model of autism. L1-79 recently demonstrated efficacy in a Phase 2 study.

About Marvel Biosciences Corp.

Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.

Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469Website: www.marvelbiotechnology.com    |   Twitter/X   |   LinkedIn

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for small to mid-sized biotech and pharmaceutical companies.

The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical evaluation. The planned Phase 1 program is designed to establish the initial safety, tolerability and pharmacokinetic profile of MB-204 in humans, while generating clinical data to inform subsequent development. This transition is supported by encouraging preclinical findings, with MB-204 demonstrating immediate, robust and durable effects, including measurable carry-over effects following cessation of treatment, across multiple mouse models relevant to neurodevelopmental disorders, including Oprm1, Rett and Fragile X models. Together, these findings provide a scientific rationale for advancing MB-204 into clinical development and establishing its initial human safety and pharmacokinetic profile.

“We are pleased to begin moving forward into a Phase I trial for MB-204 in partnership with Novatech following the recent closing of our private placement and signing of a letter-of-intent,” said Marvel’s CEO Rod Matheson. “Novatech provides end-to-end clinical trial management, site selection, regulatory and ethics submissions, biostatistics, data management, and medical writing. They have an early-phase clinical focus including First-in-Human and proof-of-concept studies. The trial will be conducted in Australia which offers a streamlined and favourable regulatory environment as well as a generous 43% tax credit. We look forward to updating the market on our single ascending dose and multiple ascending dose studies as we progress. This marks Marvel’s transition from a pre-clinical to clinical phase company.”

Corporate Update:

• The Phase I single ascending dose (SAD) study is expected to begin in Q4 of 2026. The SAD study is designed to test the safety, tolerability and pharmacokinetics (PK) of MB-204 as well as include a potential biomarker and several cognitive endpoints. The data from the SAD will inform the design of the subsequent multiple ascending dose (MAD) study.
• Marvel has previously developed a novel liquid-based formulation of MB-204 for its Phase 1 trial SAD study which improved the drug’s PK in pre-clinical studies and may facilitate administration in patient populations where swallowing solid dosage forms may present challenges. The work was conducted with a grant from the National Research Council of Canada.
• The Company is currently preparing manuscripts for scientific publication and will provide a future update on conference participation.
• In collaboration with the iBrain Inserm Lab, Marvel is planning an upcoming experiment to test the efficacy of MB-204 against Yamo Pharmaceuticals’ L1-79 (repurposed racemic N-methyl Tyrosine) in a mouse model of autism. L1-79 recently demonstrated efficacy in a Phase 2 study.

About Marvel Biosciences Corp.

Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.

Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469Website: www.marvelbiotechnology.com    |   Twitter/X   |   LinkedIn

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

GEORGE TOWN, Cayman Islands, Oct. 06, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for September 2026 on Tuesday, October 6, 2026.

These metrics include trading volume, average trading spread, and measures of volatility for Bitcoin and Ethereum. For definitions and additional information regarding these metrics, please refer to the monthly metrics packages available on investors.bullish.com.

About Bullish

Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange – an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data – a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights – a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Contacts

Media: media@bullish.com

Investor Relations: investors@bullish.com

Source: Bullish

Additional Information & Disclosures

This monthly metrics package provides certain limited purpose monthly performance results of Bullish. This information is presented without commentary and should be read together with our most recent quarterly and annual results and our filings with the U.S. Securities and Exchange Commission (SEC), which are available on our Investor Relations website at investors.bullish.com.

The information provided is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on our estimates and subject to completion of our financial closing procedures. Final results for the quarter, as reported in our SEC filings, might vary from the information provided in this monthly metrics package.

Bullish expects to release monthly metrics packages for the prior month’s performance after the end of each month.

We use our Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the SEC and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Definitions

Trading Volume represents the notional value of trades, i.e. the product of the quantity of assets transacted and the trade price at the time the transaction was executed. The quantity represents the total U.S. dollar equivalent value of matched trades transacted between a buyer and seller through our platform during the period of measurement.

Average Trading Spread represents total commissions earned from transactions on the Bullish Exchange for the period, expressed as a percentage of the trading volume for the period. Management reviews this metric, which reflects the cost of trading on the Bullish Exchange, changes in fair value of perpetual futures, and rebates, for insight into the average revenue generated per unit of trading volume on our platform.

Volatility is calculated using 1-minute price intervals from Coindesk Data’s Adaptive Diversified Liquidity Index for BTC and ETH. We determine the daily volatility by measuring the standard deviation of these minute-by-minute price changes, which provides a more granular view of price fluctuations. This daily figure is then converted to an annualized volatility by multiplying it by the square root of 365, a standard practice for making risk metrics comparable over a one-year period.

Monthly Metrics Report for September 2026
(Unaudited)
	2025													2026
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep
(B – in billions)
Trading Volume ($B)
Spot – BTC	34.6	30.9	43.2	39.2	32.8	19.9	20.8	18.2	16.4	38.2	38.4	25.9		22.5	41.8	29.1	20.9	16.8	26.9	16.7	17.6	19.9
Spot – ETH	18.3	19.2	14.9	10.9	12.0	9.5	11.1	12.8	8.8	15.1	14.1	9.6		8.4	12.9	8.0	5.4	3.4	4.9	3.0	3.7	4.5
Spot – Stablecoin	19.4	20.9	17.0	13.3	10.3	8.1	12.9	8.6	8.1	19.6	18.4	13.8		11.2	19.0	13.2	9.6	7.4	10.8	7.3	7.9	9.5
Spot – Other	4.8	3.8	2.7	2.2	2.6	2.4	4.0	4.6	4.1	4.6	4.4	2.9		3.4	3.7	2.7	2.1	2.5	2.9	2.2	6.6	8.4
Total Spot	77.1	74.8	77.7	65.5	57.6	39.9	48.8	44.3	37.3	77.5	75.3	52.2		45.4	77.4	52.9	38.0	30.0	45.5	29.1	35.8	42.2
Options								0.0	0.0	0.0	2.8	6.2		4.8	3.6	3.2	5.6	0.9	2.3	0.2	4.7	4.1
Perpetual	6.6	7.8	8.0	6.8	5.8	4.1	5.0	4.6	2.2	3.0	2.7	2.6		2.0	3.1	4.4	3.4	2.0	3.1	1.5	2.0	2.3
Total Trading Volume	83.7	82.5	85.7	72.3	63.4	44.0	53.8	48.8	39.6	80.5	80.8	61.1		52.2	84.1	60.4	46.9	32.9	50.9	30.7	42.5	48.6
Average Trading Spread (bps)
Spot	2.14	1.97	1.87	1.65	1.55	1.58	1.76	2.55	1.96	1.75	1.94	1.82		1.74	2.22	2.01	2.05	2.40	2.84	2.71	2.53	2.41
Options								1.00	0.93	1.29	1.34	1.66		1.95	2.42	1.86	2.50	1.65	0.59	1.09	0.14	0.40
Perpetual	(1.06)	(1.41)	(2.38)	(1.47)	(0.86)	(1.22)	(0.80)	(0.65)	0.21	(2.67)	(0.13)	(0.30)		(0.61)	0.37	0.09	(0.08)	(0.12)	(0.14)	1.21	(0.32)	0.38
Average Trading Spread	1.90	1.65	1.47	1.36	1.32	1.32	1.52	2.25	1.86	1.59	1.85	1.71		1.67	2.16	1.86	1.95	2.23	2.56	2.62	2.13	2.14
Monthly Average Volatility
BTC	48%	44%	50%	44%	33%	28%	27%	28%	23%	38%	45%	39%		33%	61%	48%	35%	28%	47%	32%	30%	32%
ETH	60%	78%	69%	70%	67%	54%	54%	60%	42%	58%	68%	53%		46%	82%	60%	44%	36%	67%	44%	39%	42%
* Figures presented may not sum precisely due to rounding

GEORGE TOWN, Cayman Islands, Oct. 06, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for September 2026 on Tuesday, October 6, 2026.

These metrics include trading volume, average trading spread, and measures of volatility for Bitcoin and Ethereum. For definitions and additional information regarding these metrics, please refer to the monthly metrics packages available on investors.bullish.com.

About Bullish

Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange – an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data – a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights – a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Contacts

Media: media@bullish.com

Investor Relations: investors@bullish.com

Source: Bullish

Additional Information & Disclosures

This monthly metrics package provides certain limited purpose monthly performance results of Bullish. This information is presented without commentary and should be read together with our most recent quarterly and annual results and our filings with the U.S. Securities and Exchange Commission (SEC), which are available on our Investor Relations website at investors.bullish.com.

The information provided is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on our estimates and subject to completion of our financial closing procedures. Final results for the quarter, as reported in our SEC filings, might vary from the information provided in this monthly metrics package.

Bullish expects to release monthly metrics packages for the prior month’s performance after the end of each month.

We use our Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the SEC and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Definitions

Trading Volume represents the notional value of trades, i.e. the product of the quantity of assets transacted and the trade price at the time the transaction was executed. The quantity represents the total U.S. dollar equivalent value of matched trades transacted between a buyer and seller through our platform during the period of measurement.

Average Trading Spread represents total commissions earned from transactions on the Bullish Exchange for the period, expressed as a percentage of the trading volume for the period. Management reviews this metric, which reflects the cost of trading on the Bullish Exchange, changes in fair value of perpetual futures, and rebates, for insight into the average revenue generated per unit of trading volume on our platform.

Volatility is calculated using 1-minute price intervals from Coindesk Data’s Adaptive Diversified Liquidity Index for BTC and ETH. We determine the daily volatility by measuring the standard deviation of these minute-by-minute price changes, which provides a more granular view of price fluctuations. This daily figure is then converted to an annualized volatility by multiplying it by the square root of 365, a standard practice for making risk metrics comparable over a one-year period.

Monthly Metrics Report for September 2026
(Unaudited)
	2025													2026
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep
(B – in billions)
Trading Volume ($B)
Spot – BTC	34.6	30.9	43.2	39.2	32.8	19.9	20.8	18.2	16.4	38.2	38.4	25.9		22.5	41.8	29.1	20.9	16.8	26.9	16.7	17.6	19.9
Spot – ETH	18.3	19.2	14.9	10.9	12.0	9.5	11.1	12.8	8.8	15.1	14.1	9.6		8.4	12.9	8.0	5.4	3.4	4.9	3.0	3.7	4.5
Spot – Stablecoin	19.4	20.9	17.0	13.3	10.3	8.1	12.9	8.6	8.1	19.6	18.4	13.8		11.2	19.0	13.2	9.6	7.4	10.8	7.3	7.9	9.5
Spot – Other	4.8	3.8	2.7	2.2	2.6	2.4	4.0	4.6	4.1	4.6	4.4	2.9		3.4	3.7	2.7	2.1	2.5	2.9	2.2	6.6	8.4
Total Spot	77.1	74.8	77.7	65.5	57.6	39.9	48.8	44.3	37.3	77.5	75.3	52.2		45.4	77.4	52.9	38.0	30.0	45.5	29.1	35.8	42.2
Options								0.0	0.0	0.0	2.8	6.2		4.8	3.6	3.2	5.6	0.9	2.3	0.2	4.7	4.1
Perpetual	6.6	7.8	8.0	6.8	5.8	4.1	5.0	4.6	2.2	3.0	2.7	2.6		2.0	3.1	4.4	3.4	2.0	3.1	1.5	2.0	2.3
Total Trading Volume	83.7	82.5	85.7	72.3	63.4	44.0	53.8	48.8	39.6	80.5	80.8	61.1		52.2	84.1	60.4	46.9	32.9	50.9	30.7	42.5	48.6
Average Trading Spread (bps)
Spot	2.14	1.97	1.87	1.65	1.55	1.58	1.76	2.55	1.96	1.75	1.94	1.82		1.74	2.22	2.01	2.05	2.40	2.84	2.71	2.53	2.41
Options								1.00	0.93	1.29	1.34	1.66		1.95	2.42	1.86	2.50	1.65	0.59	1.09	0.14	0.40
Perpetual	(1.06)	(1.41)	(2.38)	(1.47)	(0.86)	(1.22)	(0.80)	(0.65)	0.21	(2.67)	(0.13)	(0.30)		(0.61)	0.37	0.09	(0.08)	(0.12)	(0.14)	1.21	(0.32)	0.38
Average Trading Spread	1.90	1.65	1.47	1.36	1.32	1.32	1.52	2.25	1.86	1.59	1.85	1.71		1.67	2.16	1.86	1.95	2.23	2.56	2.62	2.13	2.14
Monthly Average Volatility
BTC	48%	44%	50%	44%	33%	28%	27%	28%	23%	38%	45%	39%		33%	61%	48%	35%	28%	47%	32%	30%	32%
ETH	60%	78%	69%	70%	67%	54%	54%	60%	42%	58%	68%	53%		46%	82%	60%	44%	36%	67%	44%	39%	42%
* Figures presented may not sum precisely due to rounding

Stockholm, 6 October 2026 – Virtune, a Swedish regulated digital asset manager, is announcing the launch of the Virtune Zcash ETP on Nasdaq Stockholm, the largest stock exchange in the Nordics.

Virtune is a Swedish asset manager and issuer of physically backed crypto exchange-traded products (ETPs). Since its launch in 2023, Virtune has gained the trust of more than 160,000 investors and today manages approximately USD 380 million in assets under management (AUM), strengthening the company’s position as one of Europe’s leading issuers of regulated crypto ETPs. The company holds more than 90% market share for crypto ETNs on Nasdaq Nordics.

About Virtune Zcash ETP

Virtune Zcash ETP is a physically backed exchange-traded product (ETP) designed to offer investors a secure and cost-effective way to gain exposure to Zcash (ZEC). This is made possible through a transparent and physically backed structure with institutional-level security.

Key information about Virtune Zcash ETP

• 1:1 exposure to ZEC
• 100% physically backed by ZEC
• 1.49% annual management fee

Virtune Zcash ETP

• Full name: Virtune Zcash ETP
• Short name: Virtune Zcash
• Ticker: VIRZEC
• Trading currency: SEK
• First day of trading: Tuesday, 6 October 2026
• ISIN: SE0030587929

About Zcash

Zcash is a payment blockchain with the option to protect payment details. Its crypto asset, ZEC, is used for payments. Launched in 2016 and built from Bitcoin’s original code, the network focuses on payment privacy. Users can choose between transparent and shielded addresses. Shielded payments use zero-knowledge proofs, a technology that lets the network verify a payment without publishing its underlying information. ZEC has a maximum supply of 21 million units.

Christopher Kock, CEO of Virtune:

“In May 2023, we launched our first product on Nasdaq Stockholm. Since then, we have worked tirelessly to expand our product offering and help Nordic investors better understand crypto assets. Today, we are pleased to introduce Virtune Zcash ETP, providing a straightforward way to gain exposure to Zcash through online brokers such as Avanza and Nordnet. The product is 100% physically backed by Zcash, held in cold storage with Coinbase.”

If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, covering updates on upcoming ETP launches and other news related to digital assets.

Press contact

Christopher Kock, CEO Virtune AB (Publ)
christopher@virtune.com
+46 70 073 45 64

Virtune, headquartered in Stockholm, is a Swedish regulated asset manager and issuer of crypto ETPs listed on regulated European exchanges. Through regulatory compliance, strategic partnerships and an experienced team, Virtune provides access to innovative and sophisticated investment products tailored to the rapidly evolving global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

Stockholm, 6 October 2026 – Virtune, a Swedish regulated digital asset manager, is announcing the launch of the Virtune Zcash ETP on Nasdaq Stockholm, the largest stock exchange in the Nordics.

Virtune is a Swedish asset manager and issuer of physically backed crypto exchange-traded products (ETPs). Since its launch in 2023, Virtune has gained the trust of more than 160,000 investors and today manages approximately USD 380 million in assets under management (AUM), strengthening the company’s position as one of Europe’s leading issuers of regulated crypto ETPs. The company holds more than 90% market share for crypto ETNs on Nasdaq Nordics.

About Virtune Zcash ETP

Virtune Zcash ETP is a physically backed exchange-traded product (ETP) designed to offer investors a secure and cost-effective way to gain exposure to Zcash (ZEC). This is made possible through a transparent and physically backed structure with institutional-level security.

Key information about Virtune Zcash ETP

• 1:1 exposure to ZEC
• 100% physically backed by ZEC
• 1.49% annual management fee

Virtune Zcash ETP

• Full name: Virtune Zcash ETP
• Short name: Virtune Zcash
• Ticker: VIRZEC
• Trading currency: SEK
• First day of trading: Tuesday, 6 October 2026
• ISIN: SE0030587929

About Zcash

Zcash is a payment blockchain with the option to protect payment details. Its crypto asset, ZEC, is used for payments. Launched in 2016 and built from Bitcoin’s original code, the network focuses on payment privacy. Users can choose between transparent and shielded addresses. Shielded payments use zero-knowledge proofs, a technology that lets the network verify a payment without publishing its underlying information. ZEC has a maximum supply of 21 million units.

Christopher Kock, CEO of Virtune:

“In May 2023, we launched our first product on Nasdaq Stockholm. Since then, we have worked tirelessly to expand our product offering and help Nordic investors better understand crypto assets. Today, we are pleased to introduce Virtune Zcash ETP, providing a straightforward way to gain exposure to Zcash through online brokers such as Avanza and Nordnet. The product is 100% physically backed by Zcash, held in cold storage with Coinbase.”

If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, covering updates on upcoming ETP launches and other news related to digital assets.

Press contact

Christopher Kock, CEO Virtune AB (Publ)
christopher@virtune.com
+46 70 073 45 64

Virtune, headquartered in Stockholm, is a Swedish regulated asset manager and issuer of crypto ETPs listed on regulated European exchanges. Through regulatory compliance, strategic partnerships and an experienced team, Virtune provides access to innovative and sophisticated investment products tailored to the rapidly evolving global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

FORT WORTH, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — RANGE RESOURCES CORPORATION (NYSE: RRC) announced today that its third quarter 2026 financial results news release will be issued Tuesday, October 27 after the close of trading on the New York Stock Exchange.

A conference call to review the financial results is scheduled on Wednesday, October 28 at 9:00 a.m. ET (8:00 a.m. CT). A webcast of the call may be accessed at www.rangeresources.com. The webcast will be archived for replay on the Company’s website until November 27, 2026.

RANGE RESOURCES CORPORATION (NYSE: RRC) is a leading U.S. independent natural gas and NGL producer with operations focused in the Appalachian Basin. The Company is headquartered in Fort Worth, Texas. More information about Range can be found at www.rangeresources.com.

SOURCE: Range Resources Corporation

Range Investor Contacts:

Laith Sando, SVP – Corporate Strategy & Investor Relations
817-869-4267
lsando@rangeresources.com

FORT WORTH, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — RANGE RESOURCES CORPORATION (NYSE: RRC) announced today that its third quarter 2026 financial results news release will be issued Tuesday, October 27 after the close of trading on the New York Stock Exchange.

A conference call to review the financial results is scheduled on Wednesday, October 28 at 9:00 a.m. ET (8:00 a.m. CT). A webcast of the call may be accessed at www.rangeresources.com. The webcast will be archived for replay on the Company’s website until November 27, 2026.

RANGE RESOURCES CORPORATION (NYSE: RRC) is a leading U.S. independent natural gas and NGL producer with operations focused in the Appalachian Basin. The Company is headquartered in Fort Worth, Texas. More information about Range can be found at www.rangeresources.com.

SOURCE: Range Resources Corporation

Range Investor Contacts:

Laith Sando, SVP – Corporate Strategy & Investor Relations
817-869-4267
lsando@rangeresources.com

CHANTILLY, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) will release third-quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The company will host a conference call at 8:00 a.m. Eastern Time that day to discuss its earnings results and guidance, followed by a question-and-answer session.

Access to a webcast of the live conference call can be obtained through the Investor Relations section of the company’s website (https://investors.parsons.com). Those parties interested in participating via telephone may register on the Investor Relations website or by clicking here.

A replay will be available on the company’s website approximately two hours after the conference call and continuing for one year.

About Parsons Corporation

Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Contacts:

Media
Bernadette Miller
Parsons Corporation
+1 980.253.9781
Bernadette.Miller@parsons.com

Investor Relations
Dave Spille
Parsons Corporation
+1 571.775.0408
Dave.Spille@Parsons.us